ArticleBMC nutrition2026
Obesity and subclinical kidney injury: a biomarker based assessment in Asian Indian adults.
Article in BMC nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundThe prevalence of obesity is rapidly increasing, presenting a significant risk for obesity-related glomerulopathy. Thus, it is crucial to prioritize early detection of obesity related glomerulopathy. Biomarkers, such as NGAL, TIMP-2, and IGFBP-7 have shown promise in detecting subclinical kidney injury. The study aimed to explore whether obese individuals exhibit higher levels of NGAL, TIMP-2 and IGFB7 as compared to non-obese individuals.
methodsA total of 160 adults without any comorbidities, participated in this cross-sectional study. Participants were categorized into four BMI-based groups: Group A (normal weight, BMI 18.0–24.9 kg/m²), Group B (overweight, BMI 25.0–34.9 kg/m²), Group C (obese, BMI 35.0–39.9 kg/m²), and Group D (morbidly obese, BMI ≥ 40.0 kg/m²). NGAL was measured from serum samples, while TIMP2 and IGFBP7 were extracted from urine samples. All biomarkers were assessed using the ELISA method. Kruskal-Wallis test and spearman correlation were performed to evaluate the association between these biomarkers and BMI-related factors.
resultsWe observed a statistically significant difference in the median serum NGAL levels (p < 0.001). However, no significant differences were found in the median levels of TIMP-2 or IGFBP-7 across the BMI categories. We also found a positive association between serum NGAL and various parameters of adiposity. However, this correlation also remained insignificant for urine TIMP-2 and urine IGFBP-7.
conclusionsSerum NGAL levels are significantly elevated in individuals with higher degrees of obesity and shows positive correlation with various measures of adiposity. Our findings highlight the need of early screening for renal stress in individuals with obesity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.